Table 4.
Vitamin K metabolites and dependent proteins at baseline and at 1 and 6 weeks post-phytomenadione administration in pseudoxanthoma elasticum (PXE) patients, in non-carriers and in ABCC6 carriers.
| Group | Baseline | Week 1 | Week 6 | Significance(along time) |
|---|---|---|---|---|
| Vitamin K metabolites | ||||
| Serum MK-4 (ng/mL) | ||||
| Non-carriers | 15.5 ± 5.2 | 25.4 ± 12.4 | 23.7 ± 32.0 | ns |
| ABCC6 carriers | 20.0 ± 14.0 | 27.1 ± 12.4 | 23.1 ± 6.9 | ns |
| PXE | 28.8 ± 26.9 | 38.3 ± 32.0 | 41.6 ± 17.8 | ns |
| Significance (among groups) | *§ | *§ | *§ | |
| Serum MK-7 (ng/mL) | ||||
| Non-carriers | 25.1 ± 8.8 | 22.8 ± 16.9 | 18.4 ± 7.8 | ns |
| ABCC6 carriers | 14.8 ± 11.3 | 23.4 ± 8.7 | 22.3 ± 8.0 | ns |
| PXE | 12.2 ± 8.7 | 23.0 ± 9.0 | 22.3 ± 2.0 | ns |
| Significance (among groups) | ns | ns | ns | |
| Urinary 5C-vitamin K metabolite (mg/g) | ||||
| Non-carriers | 6.86 ± 2.71 | 7.34 ± 2.82 | 4.21 ± 1.88 | ns |
| ABCC6 carriers | 3.87 ± 3.32 | 4.53 ± 3.53 | 3.15 ± 3.12 | ns |
| PXE | 3.27 ± 2.61 | 4.23 ± 4.35 | 3.63 ± 2.25 | ns |
| Significance (among groups) | * | * | ns | |
| Urinary 7C-vitamin K metabolite (mg/g) | ||||
| Non-carriers | 3.41 ± 1.48 | 3.98 ± 1.56 | 2.65 ± 1.22 | ns |
| ABCC6 carriers | 1.54 ± 1.16 | 2.55 ± 1.89 | 1.64 ± 0.90 | ns |
| PXE | 2.21 ± 1.33 | 2.49 ± 1.59 | 1.96 ± 1.28 | ns |
| Significance (among groups) | ns | ns | ns | |
| Total urinary vitamin K metabolites (mg/g) | ||||
| Non-carriers | 10.2 ± 4.19 | 11.3 ± 4.06 | 6.86 ± 2.89 | ns |
| ABCC6 carriers | 5.40 ± 4.45 | 7.07 ± 5.27 | 4.79 ± 3.80 | ns |
| PXE | 5.48 ± 3.71 | 6.72 ± 5.71 | 5.59 ± 3.26 | ns |
| Significance (among groups) | ns | ns | ns | |
| Vitamin K-dependent proteins | ||||
| Serum GAS6 (ng/mL) | ||||
| Non-carriers | 58.7 ± 7.61 | 52.8 ± 18.7 | 41.2 ± 5.4 | p < 0.05 |
| ABCC6 carriers | 51.9 ± 9.18 | 46.3 ± 7.1 | 40.6 ± 7.4 | p < 0.05 |
| PXE | 47.3 ± 9.14 | 47.9 ± 11.4 | 38.9 ± 8.6 | p < 0.05 |
| Significance (among groups) | ns | ns | ns | |
| Serum Glu-Osteocalcin (ng/mL) | ||||
| Non-carriers | 7.0 ± 1.5 | 3.1 ± 1.5 | 5.9 ± 2.2 | p < 0.05 |
| ABCC6 carriers | 14.6 ± 8.8 | 11.5 ± 8.9 | 13.9 ± 8.8 | p < 0.05 |
| PXE | 11.7 ± 5.4 | 7.2 ± 2.6 | 10.1 ± 4.9 | p < 0.05 |
| Significance (among groups) | ns | ns | ns | |
| Serum Gla-Osteocalcin (ng/mL) | ||||
| Non-carriers | 12.4 ± 5.5 | 18.6 ± 4.9 | 13.0 ± 6.0 | p < 0.05 |
| ABCC6 carriers | 13.7 ± 5.9 | 20.2 ± 8.9 | 14.2 ± 5.4 | p < 0.05 |
| PXE | 12.6 ± 8.3 | 15.9 ± 9.1 | 14.3 ± 9.6 | p < 0.05 |
| Significance (among groups) | ns | ns | ns | |
| PIVKA-II (ng/ml) | ||||
| Non-carriers | 1.35 ± 0.56 | 1.13 ± 0.48 | 1.17 ± 0.72 | ns |
| ABCC6 carriers | 1.56 ± 0.58 | 1.29 ± 0.44 | 1.33 ± 0.41 | ns |
| PXE | 1.25 ± 0.38 | 1.13 ± 0.44 | 1.11 ± 0.50 | ns |
| Significance (among groups) | ns | ns | ns | |
| Serum Fetuin (ng/mL) | ||||
| Non-carriers | 893 ± 535 | 843 ± 498 | 925 ± 646 | ns |
| ABCC6 carriers | 959 ± 453 | 927 ± 364 | 813 ± 325 | ns |
| PXE | 795 ± 146 | 787 ± 227 | 834 ± 223 | ns |
| Significance (among groups) | ns | ns | ns | |
*p < 0.05 ABCC6 carriers or PXE versus non-carriers.
§p < 0.05 ABCC6 carriers versus PXE.
Data shown as mean ± SD.